Individuals with obesity were at least two times more likely to develop certain types of cancer and 3.5 times more likely to die from from the disease than those who had weight-loss surgery, according to a new study presented ...
Jun 7, 2022
0
6
A drug combination targeting multiple mutant versions of cancer's "death star" protein has shown promise in a small, early-phase clinical trial for some patients with advanced lung, ovarian and thyroid cancer.
Jun 6, 2022
0
541
For patients with low-risk thyroid cancer undergoing thyroidectomy, follow-up without use of radioiodine is noninferior to ablation with radioiodine, according to a study published in the March 10 issue of the New England ...
Mar 10, 2022
0
4
Thyroid cancer is the most common type of endocrine cancer in children. Because it is bilateral—affecting both sides (lobes) of the thyroid—in more than one third of pediatric patients, initial treatment typically involves ...
Mar 1, 2022
0
8
January is Thyroid Awareness Month, which makes this a good time to learn about thyroid cancer risk factors.
Jan 26, 2022
0
4
Researchers at the Paul Scherrer Institute PSI have tested various methods to check how effective they are in combatting certain types of cancer. They found a combination of two preparations to be much more effective than ...
Dec 15, 2021
0
5
Exposure in utero to a drug used to prevent miscarriage can lead to an increased risk of developing cancer, according to researchers at The University of Texas Health Science Center at Houston (UTHealth Houston).
Nov 9, 2021
0
8
Firefighters who worked at the World Trade Center following the 9/11 attacks in 2001 are 13% more likely than colleagues who didn't work at the site to develop cancer, particularly prostate and thyroid cancer, finds research ...
Sep 11, 2021
0
16
A lump in the thyroid gland is called a thyroid nodule, and 5-10% of all thyroid nodules are diagnosed as thyroid cancer. Thyroid cancer has a good prognosis, a high survival rate, and a low recurrence rate, so early diagnosis ...
Jul 9, 2021
0
14
Results from the multi-cohort Phase I/II ARROW clinical trial, conducted by The University of Texas MD Anderson Cancer Center researchers, showed that a once-daily dose of pralsetinib, a highly selective RET inhibitor, was ...
Jun 10, 2021
0
1
